[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656262":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":43,"studyPopulation":40,"armGroups":44,"interventions":57,"overallOfficials":67,"centralContacts":71,"locations":40,"responsibleParty":81,"collaborators":40,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":40,"enrollmentInfo":93,"targetDuration":40,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":110,"whyStopped":40,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":40},{"fullName":5,"class":6},"Instituto Nacional de Cancerologia, Columbia","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Objective Local Tumor Response Rate Assessed by RECIST 1.1","The proportion of patients achieving an objective local tumor response, defined as either a Complete Response (CR) or a Partial Response (PR), evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","Exactly 3 months (12 weeks) from the date of randomization",{"measure":14,"description":15,"timeFrame":16},"Change in Quality of Life Assessed by FACT-H&N","Mean change from baseline in patient-reported quality of life, measured by the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H\\&N) questionnaire. The FACT-H\\&N assesses physical, social\u002Ffamily, emotional, and functional well-being, along with head and neck specific concerns. The total score ranges from 0 to 156, where higher scores indicate a better quality of life\n\nAssessment of Cancer Therapy-Head and Neck (FACT-H\\&N) questionnaire. The FACT-H\\&N assesses physical, social\u002Ffamily, emotional, and functional well-being, along with head and neck specific concerns. Higher scores indicate a better quality of life.","Baseline, at the end of radiotherapy treatment, 3 months, and 6 months from the date of randomization",[18],{"measure":19,"description":20,"timeFrame":21},"Incidence of Acute Treatment-Related Toxicity","The proportion of patients experiencing acute adverse events (Grade 2 or higher) associated with the radiotherapy regimens. Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.","From the start of treatment up to 3 months from the date of randomization",[23,27,31],{"measure":24,"description":25,"timeFrame":26},"Incidence of Late Treatment-Related Toxicity","The proportion of patients experiencing new or persistent late adverse events (Grade 2 or higher) associated with the radiotherapy regimens. Toxicities will be graded according to the CTCAE version 5.0.","At 3 months and 6 months from the date of randomization",{"measure":28,"description":29,"timeFrame":30},"Treatment Feasibility and Tolerance","The proportion of patients who successfully complete the prescribed radiotherapy regimen, defined as receiving 90% or more of the planned radiation dose\u002Ffractions without treatment abandonment, major modifications, or unscheduled interruptions longer than 7 consecutive days due to toxicity or clinical deterioration.","Through the completion of the prescribed radiotherapy regimen, an average of 4 to 8 weeks",{"measure":32,"description":33,"timeFrame":34},"Overall Survival (OS)","Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients alive at the end of their follow-up period will be censored.","Up to 6 months from the date of randomization",{"allocation":36,"interventionModel":37,"interventionModelDescription":38,"primaryPurpose":39,"observationalModel":40,"timePerspective":40,"maskingInfo":41},"RANDOMIZED","PARALLEL","Participants will be assigned in a 1:1 ratio using centralized randomization with permuted blocks of 4, stratified by tumor volume, to receive either the Quad Shot or the Split Course radiotherapy regimen.","SUPPORTIVE_CARE",null,{"masking":42,"maskingDescription":40,"whoMasked":40},"NONE","The optimal palliative radiotherapy regimen for incurable head and neck squamous cell carcinoma remains undefined. The standard approach at the Instituto Nacional de Cancerologia is the split-course regimen. Although effective for local symptom control, it requires a prolonged treatment course and is associated with significant acute toxicities that can compromise the comfort and quality of life of frail patients with a limited life expectancy.\n\nThe Quad Shot regimen, a hypofractionated approach initially evaluated in the RTOG 8502 trial for pelvic malignancies, offers a substantially shorter treatment duration. It has shown promising symptom control and lower toxicity profiles in retrospective and early phase studies for head and neck cancers. However, there is a lack of prospective, randomized data directly comparing the Quad Shot regimen to the split course approach.\n\nThis is a single-center, open-label, exploratory phase II randomized controlled trial designed to compare the efficacy, safety, and tolerability of the Quad Shot regimen versus the split course regimen. A total of 40 adult patients will be centrally randomized in a 1:1 ratio using permuted blocks of 4, stratified by tumor volume, to receive either the experimental hypofractionated regimen or the active comparator.\n\nTo ensure data quality, the study will utilize an institutional REDCap database for electronic case report forms (eCRF) with double data entry and monthly quality control checks. Quality assurance of the radiotherapy plans will be enforced through peer review and patient-specific pre-treatment dosimetry.\n\nA formal interim analysis for safety and futility is planned once 50% of the recruitment target is reached. Final statistical analyses will follow the Intention-To-Treat (ITT) principle. Given the palliative nature of the cohort, competitive mortality will be factored into longitudinal statistical models (such as mixed-effects models) to adequately manage missing data without distorting efficacy and quality of life estimations.",[45,51],{"label":46,"type":47,"description":48,"interventionNames":49},"Quad Shot Regimen","EXPERIMENTAL","Patients assigned to this arm will receive the experimental Quad Shot hypofractionated palliative radiotherapy regimen. Treatment is delivered using Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT).",[50],"Radiation: Quad Shot Radiotherapy",{"label":52,"type":53,"description":54,"interventionNames":55},"Active Comparator: Split Course Regimen","ACTIVE_COMPARATOR","Patients assigned to this arm will receive the standard Split Course fractionated palliative radiotherapy regimen. Treatment is delivered using Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT).",[56],"Radiation: Split Course Radiotherapy",[58,63],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":40},"RADIATION","Quad Shot Radiotherapy","A hypofractionated palliative radiotherapy regimen delivering a dose of 14.8 Gy divided into 4 fractions. Each fraction is 3.7 Gy, administered twice a day (with an interval of at least 6 hours between fractions) for 2 consecutive days. This cycle can be repeated up to three times with a resting interval of 3 to 4 weeks between each cycle, provided there is no limiting toxicity or disease progression.",[46],{"type":59,"name":64,"description":65,"armGroupLabels":66,"otherNames":40},"Split Course Radiotherapy","A fractionated palliative radiotherapy regimen administered in two phases. The total dose is 60 Gy divided into 20 daily fractions of 3 Gy each. A planned resting interval of 3 to 4 weeks is introduced between the two treatment phases to maximize symptom control while maintaining acceptable toxicity.",[52],[68],{"name":69,"affiliation":5,"role":70},"Oscar Gamboa, Md","PRINCIPAL_INVESTIGATOR",[72,77],{"name":73,"role":74,"phone":75,"phoneExt":40,"email":76},"Oscar Gamboa, Medical Doctor","CONTACT","+57 3112018714","ogamboa@cancer.gov.co",{"name":78,"role":74,"phone":79,"phoneExt":40,"email":80},"Santiago Ardila Giraldo, Medical Doctor","+57 3147261176","s.ardilagiraldo@gmail.com",{"type":82,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100656262","quad-shot-versus-split-course-radiotherapy-in-incurable-head-and-neck-cancer-100656262",false,"NCT07823309","Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer","Comparison of Two Hypofractionated Radiotherapy Regimens for the Palliative Management of Patients With Head and Neck Cancers: Quad Shot Versus Split Course","QSSC-HN","Inclusion Criteria:\n\n* Adult patients (18 years and older) with a histopathological diagnosis of incurable squamous cell carcinoma of the head and neck, not candidates for curative-intent treatment.\n* Metastatic or locally advanced unresectable disease, in a strictly palliative setting.\n* Medical indication for palliative radiotherapy.\n* Performance status: Karnofsky 50 or higher or ECOG 3 or lower.\n* Clinical capacity to receive radiotherapy in an outpatient setting.\n* Estimated life expectancy greater than 3 months.\n* Presence of at least one measurable lesion according to RECIST 1.1 criteria.\n* Logistical capacity and willingness to adhere to follow-up clinical and radiological controls up to 6 months post-treatment.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of previous radiotherapy to the same anatomical region to be treated.\n* Diagnosis of a second active malignancy that could interfere with the evaluation of oncological outcomes.\n* Presence of clinical instability or severe comorbidities that contraindicate radiotherapy treatment.\n* Severe cognitive or psychiatric alterations that prevent the understanding of the nature of the study, signing the consent form, or adherence to the protocol.\n* Women who are pregnant or breastfeeding","ALL","18 Years",{"count":94,"type":95},40,"ESTIMATED","INTERVENTIONAL",[98],"NA","Head and neck cancer in its advanced, incurable stage causes severe symptoms such as pain, trouble swallowing, and bleeding. Palliative radiation therapy is frequently used to relieve these symptoms and improve the patient's quality of life. Currently, a standard treatment approach is the \"Split Course\" regimen, which takes several weeks and can cause side effects that are difficult for patients to tolerate. This study aims to evaluate a shorter, alternative radiation treatment called \"Quad Shot.\"\n\nThe hypothesis of this study is that the Quad Shot regimen will be as effective as the Split Course regimen in shrinking the tumor and controlling local symptoms, but will offer a better quality of life by reducing the overall treatment time and the severity of side effects. To test this, researchers will assign participants by chance to receive either the Quad Shot or the Split Course regimen. The research team will closely monitor tumor response, treatment side effects, and patients' quality of life for up to six months.",[101,102],"Head and Neck Neoplasms","Squamous Cell Carcinoma of Head and Neck",[104,105,106,107,108,109],"Palliative Radiotherapy","Radiation Dose Hypofractionation","Quad Shot","Split Course","Quality of Life","Cancer Pain","NOT_YET_RECRUITING","2026-09-29",{"date":113,"type":114},"2026-10-02","ACTUAL",{"date":116,"type":95},"2027-01-01",{"date":118,"type":95},"2028-12-31",{"name":5,"class":6}]